Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Barbara Hero

Showing results (11-20 of 141) with videos related to

Pageof 15
Sort By:
Cancer Letters|July 16, 2005
Risk estimation in localized unresectable single copy MYCN neuroblastoma by the status of chromosomes 1p and 11qThorsten Simon, Rüdiger Spitz, Barbara Hero, et al.
Pediatric Blood & Cancer|September 27, 2021
Hypercalcemia is a frequent side effect of 13-cis-retinoic acid treatment in patients with high-risk neuroblastomaMarc Hoemberg, Ruth Schwenzfeur, Frank Berthold, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 9, 2004
The tumor-associated antigen PRAME is universally expressed in high-stage neuroblastoma and associated with poor outcomeAndré Oberthuer, Barbara Hero, Rüdiger Spitz, et al.
European Journal of Cancer (Oxford, England : 1990)|April 22, 2008
The prognostic impact of functional imaging with (123)I-mIBG in patients with stage 4 neuroblastoma >1 year of age on a high-risk treatment protocol: results of the German Neuroblastoma Trial NB97Matthias Schmidt, Thorsten Simon, Barbara Hero, et al.
Journal of Medical Screening|July 31, 2015
Correction factors for self-selection when evaluating screening programmesClaudia Spix, Frank Berthold, Barbara Hero, et al.
Biometrical Journal. Biometrische Zeitschrift|October 15, 2024
Confirmatory Adaptive Designs for Clinical Trials With Multiple Time-to-Event Outcomes in Multi-state Markov ModelsMoritz Fabian Danzer, Andreas Faldum, Thorsten Simon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 4, 2013
Role of surgery in the treatment of patients with stage 4 neuroblastoma age 18 months or older at diagnosisThorsten Simon, Beate Häberle, Barbara Hero, et al.
Pediatric Hematology and Oncology|January 14, 2017
Liver transplantation as a potentially lifesaving measure in neuroblastoma stage 4STill Holsten, Tobias Schuster, Enke Grabhorn, et al.
JAMA Network Open|November 3, 2023
Extrauterine Placental Perfusion and Oxygenation in Infants With Very Low Birth Weight: A Randomized Clinical TrialBenjamin Kuehne, Berthold Grüttner, Martin Hellmich, et al.
The American Journal of Pathology|February 25, 2003
Full-length telomerase reverse transcriptase messenger RNA is an independent prognostic factor in neuroblastomaMatthias Krams, Barbara Hero, Frank Berthold, et al.
Pageof 15

Showing results (11-20 of 141) with videos related to

Sort By:
Pageof 15
Cancer Letters|July 16, 2005
Risk estimation in localized unresectable single copy MYCN neuroblastoma by the status of chromosomes 1p and 11qThorsten Simon, Rüdiger Spitz, Barbara Hero, et al.
Pediatric Blood & Cancer|September 27, 2021
Hypercalcemia is a frequent side effect of 13-cis-retinoic acid treatment in patients with high-risk neuroblastomaMarc Hoemberg, Ruth Schwenzfeur, Frank Berthold, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 9, 2004
The tumor-associated antigen PRAME is universally expressed in high-stage neuroblastoma and associated with poor outcomeAndré Oberthuer, Barbara Hero, Rüdiger Spitz, et al.
European Journal of Cancer (Oxford, England : 1990)|April 22, 2008
The prognostic impact of functional imaging with (123)I-mIBG in patients with stage 4 neuroblastoma >1 year of age on a high-risk treatment protocol: results of the German Neuroblastoma Trial NB97Matthias Schmidt, Thorsten Simon, Barbara Hero, et al.
Journal of Medical Screening|July 31, 2015
Correction factors for self-selection when evaluating screening programmesClaudia Spix, Frank Berthold, Barbara Hero, et al.
Biometrical Journal. Biometrische Zeitschrift|October 15, 2024
Confirmatory Adaptive Designs for Clinical Trials With Multiple Time-to-Event Outcomes in Multi-state Markov ModelsMoritz Fabian Danzer, Andreas Faldum, Thorsten Simon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 4, 2013
Role of surgery in the treatment of patients with stage 4 neuroblastoma age 18 months or older at diagnosisThorsten Simon, Beate Häberle, Barbara Hero, et al.
Pediatric Hematology and Oncology|January 14, 2017
Liver transplantation as a potentially lifesaving measure in neuroblastoma stage 4STill Holsten, Tobias Schuster, Enke Grabhorn, et al.
JAMA Network Open|November 3, 2023
Extrauterine Placental Perfusion and Oxygenation in Infants With Very Low Birth Weight: A Randomized Clinical TrialBenjamin Kuehne, Berthold Grüttner, Martin Hellmich, et al.
The American Journal of Pathology|February 25, 2003
Full-length telomerase reverse transcriptase messenger RNA is an independent prognostic factor in neuroblastomaMatthias Krams, Barbara Hero, Frank Berthold, et al.
Pageof 15